1. Ultra-performance LC–MS/MS study of the pharmacokinetic interaction of imatinib with selected vitamin preparations in rats
   Hadir M Maher et al, 2018, Bioanalysis CrossRef
2. Pharmacology and pharmacokinetics of imatinib in pediatric patients
   Meinolf Suttorp et al, 2018, Expert Review of Clinical Pharmacology CrossRef
3. UV increases skin-derived 1α,25-dihydroxyvitamin D3 production, leading to MMP-1 expression by altering the balance of vitamin D and cholesterol synthesis from 7-dehydrocholesterol
   Mi Hee Shin et al, 2019, The Journal of Steroid Biochemistry and Molecular Biology CrossRef
4. Off‑target effect of imatinib and nilotinib on human vitamin D3 metabolism
   Lysann Kroschwald et al, 2017, Molecular Medicine Reports CrossRef
5. Adverse effects of imatinib in children with chronic myelogenous leukemia
   Worawut Choeyprasert et al, 2017, Pediatrics International CrossRef
6. Imatinib inhibits the regrowth of human colon cancer cells after treatment with 5-FU and cooperates with vitamin D analogue PRI-2191 in the downregulation of expression of stemness-related genes in 5-FU refractory cells
   Agnieszka Kotlarz et al, 2019, The Journal of Steroid Biochemistry and Molecular Biology CrossRef
7. Imatinib mesylate and nilotinib decrease synthesis of bone matrix in�vitro
   Lysann Kroschwald et al, 2019, Oncology Letters CrossRef
8. Side Effects and Sequelae of Treatment for Chronic Myeloid Leukemia in Childhood and Adolescence
   Meinolf Suttorp et al, 2021, Late Treatment Effects and Cancer Survivor Care in the Young CrossRef
9. Identification of kinase inhibitors that rule out the CYP27B1-mediated activation of vitamin D: an integrated machine learning and structure-based drug designing approach
   Kanupriya Mahajan et al, 2021, Molecular Diversity CrossRef
10. Safety and efficacy of Vitamin D3supplementation with Imatinib in Chronic Phase- Chronic Myeloid Leukaemia: an Exploratory Randomized Controlled Trial
    Arkapal Bandyopadhyay et al, 2023, BMJ Open CrossRef
11. Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters
    Mervat M. Omran et al, 2022, Current Therapeutic Research CrossRef
12. Studying Side Effects of Tyrosine Kinase Inhibitors in a Juvenile Rat Model with Focus on Skeletal Remodeling
    Josephine T. Tauer et al, 2018, Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy CrossRef
13. Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia
    Jill Samis et al, 2016, Pediatric Blood & Cancer CrossRef
14. Unlocking the Mechanisms of Cutaneous Adverse Drug Reactions: Activation of the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway by EGFR Inhibitors Triggers Keratinocyte Differentiation and Polarization of Epidermal Immune Responses
    Thomas Ondet et al, 2021, JID Innovations CrossRef